Program
hyaluronidase (human recombinant)
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.
Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenxits history only | 2211 open or running | phase 4since Oct 7, 2024 | Feb 20, 2020 | Mar 2027phase 2 · NCT06655155 |
| Halozyme Therapeuticsits history only | 200 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Takedaits history only | 60 open or running | phase 3since Dec 23, 2008 | Oct 29, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 42 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | Aug 31, 2029phase 2 · NCT07503340 |
| Baxter Healthcareits history only | 30 open or running | phase 4since Dec 10, 2008 | Dec 10, 2008 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Aug 6, 2015 | Aug 6, 2015 | none ahead |
Also a collaborator on its studies: BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Apr 4, 2006.
- Aug 14, 2024Phase 3 study in Myasthenia Gravisargenx · NCT06558279 · 141 enrolled · United States, Australia, Austria and more
- Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT06637072 · 23 enrolled · United States
- Oct 22, 2024Phase 2 study in Scleroderma, Systemicargenx · NCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
- Nov 10, 2024Phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847 · 631 enrolled · United States, Argentina, Australia and more
- Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)argenx · NCT06909214 · 30 planned · United States
- Feb 24, 2026Fosun Pharma’s first study: phase 1 study in Healthy Adult MaleNew to Fosun PharmaFosun Pharma · NCT07484893 · 24 planned · China
- Mar 25, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT07503340 · 25 planned
- Apr 30, 2026Phase 3 study in Graves Diseaseargenx · NCT07570316 · 230 planned · United States, Georgia, United Kingdom
- May 13, 2026Phase 3 study in Graves Diseaseargenx · NCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
- Jun 18, 2026Phase 1 study in Multiple SclerosisHoffmann-La Roche · NCT07667322 · 75 enrolled · United States, Brazil, Mexico and more
- Jul 29, 2026Phase 2 study in Sjogrens Diseaseargenx · NCT07760818 · 75 planned
- Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
- Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798
- Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925
Ahead
- Mar 2027Primary completion: phase 2 study in Scleroderma, Systemicargenx · NCT06655155
- Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT04280718
- Jul 2027Primary completion: phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847
- Sep 2027Primary completion: phase 3 study in Myasthenia Gravisargenx · NCT06392386
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 57 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07760818Sjogrens Disease | 2 | Not yet recruiting | argenx | Jul 28, 2028 | 75 |
| NCT07667322Multiple Sclerosis · United States, Brazil, Mexico and more | 1 | Active, not recruiting | Hoffmann-La Roche | Sep 1, 2026 | 75 |
| NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more | 3 | Recruiting | argenx | Jun 2028 | 230 |
| NCT07570316Graves Disease · United States, Georgia, United Kingdom | 3 | Recruiting | argenx | Jun 2028 | 230 |
| NCT07503340Multiple Sclerosis, Relapsing-Remitting | 2 | Not yet recruiting | Hoffmann-La Roche | Aug 31, 2029 | 25 |
| NCT07484893Healthy Adult Male · China | 1 | Not yet recruiting | Fosun Pharma | Aug 25, 2026 | 24 |
| NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States | 4 | Recruiting | argenx | Aug 2026 | 30 |
| NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | argenx | Jul 2027 | 631 |
| NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more | 2 | Active, not recruiting | argenx | Mar 2027 | 87 |
| NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 4 | Completed | argenx | Feb 19, 2026 | 23 |
| NCT06558279Myasthenia Gravis · United States, Australia, Austria and more | 3 | Active, not recruiting | argenx | Jan 12, 2026 | 141 |
| NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | argenx | Sep 2027 | 12 |
| NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more | 3 | Terminated | argenx | Dec 15, 2025 | 105 |
| NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | argenx | Dec 15, 2025 | 102 |
| NCT05979441Myositis · United States, Argentina, Austria and more | 3 | By invitation | argenx | Sep 2028 | 240 |
| NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | argenx | Mar 20, 2025 | 64 |
| NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Completed | argenx | Sep 13, 2024 | 98 |
| NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | argenx | Oct 2027 | 173 |
| NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more | 3 | Completed | argenx | Dec 31, 2024 | 184 |
| NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more | 3 | Completed | argenx | Nov 2, 2021 | 110 |
| NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | argenx | Oct 9, 2023 | 207 |
| NCT04598477Pemphigus · United States, Australia, Bulgaria and more | 3 | Terminated | argenx | Mar 25, 2024 | 183 |
| NCT04598451Pemphigus · United States, Australia, Bulgaria and more | 3 | Completed | argenx | Aug 22, 2023 | 222 |
| NCT04564066Healthy Volunteers · Netherlands | 1 | Completed | argenx | Dec 24, 2020 | 54 |
| NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more | 2 | Active, not recruiting | argenx | Apr 30, 2027 | 229 |
| NCT04045028Multiple Myeloma · United States, Korea, Republic of | 1 | Terminated | Hoffmann-La Roche | Mar 28, 2023 | 41 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT02519452Multiple Myeloma · United States, Denmark, France and more | 1 | Completed | Johnson & Johnson | Dec 13, 2017 | 120 |
| NCT01848990Diabetes Mellitus, Type 1 · United States | 4 | Completed | Halozyme Therapeutics | Feb 2014 | 456 |
| NCT01756157Angioedemas, Hereditary · United States, Germany, Spain and more | 2 | Completed | Takeda | Sep 13, 2013 | 47 |
| NCT01572012Healthy · United States | 1 | Completed | Halozyme Therapeutics | Nov 2013 | 12 |
| NCT01526733Diabetes Mellitus, Type 1 · United States | 4 | Completed | Halozyme Therapeutics | Aug 2012 | 25 |
| NCT01485796Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Jan 1, 2013 | 54 |
| NCT01426763Angioedemas, Hereditary · United States | 2 | Completed | Takeda | Nov 28, 2011 | 12 |
| NCT01275131Diabetes Mellitus, Type 1 · United States | 1 | Completed | Halozyme Therapeutics | Dec 2011 | 45 |
| NCT01194258Diabetes Mellitus, Type 2 · United States | 2 | Completed | Halozyme Therapeutics | Aug 2011 | 132 |
| NCT01194245Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Aug 2011 | 135 |
| NCT01175213Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Aug 6, 2013 | 66 |
| NCT01120431Dehydration | 4 | Withdrawn | Baxter Healthcare | May 2010 | 0 |
| NCT01116102Dehydration · United States | 4 | Terminated | Baxter Healthcare | May 2010 | 20 |
| NCT00979875Insulin Resistance · United States | 1 | Completed | Halozyme Therapeutics | Feb 2010 | 14 |
| NCT00928447Dermatitis, Allergic Contact · United States | 2 | Completed | Halozyme Therapeutics | Sep 13, 2009 | 22 |
| NCT00916357Diabetes Mellitus, Type 2 · United States | 2 | Completed | Halozyme Therapeutics | Nov 2009 | 23 |
| NCT00883558Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Feb 2010 | 48 |
| NCT00862849Diabetes Mellitus · United States | 1 | Completed | Halozyme Therapeutics | Jun 2009 | 22 |
| NCT00814320Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | Takeda | Nov 11, 2010 | 89 |
| NCT00807963Risk Factors for or a Diagnosis of Osteoporosis · United States | 1 | Completed | Halozyme Therapeutics | Sep 21, 2009 | 31 |
| NCT00807885Dehydration · United States | 4 | Completed | Baxter Healthcare | Jan 2009 | 100 |
| NCT00782587Non-Muscle Invasive Bladder Neoplasms · United States | 1 | Completed | Halozyme Therapeutics | Mar 2009 | 14 |
| NCT00782106Primary Immunodeficiency Diseases · United States | 2 | Completed | Takeda | Nov 1, 2007 | 11 |
| NCT00774800Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Mar 2009 | 22 |
| NCT00773175Dehydration · United States | 4 | Completed | Halozyme Therapeutics | Nov 2009 | 148 |
| NCT00656370Healthy · United States | 4 | Completed | Halozyme Therapeutics | Jan 30, 2008 | 15 |
| NCT00593281Pain · United States | 3 | Completed | Halozyme Therapeutics | Oct 2006 | 13 |
| NCT00435604Healthy | 1 | Completed | Halozyme Therapeutics | 15 | |
| NCT00318643Urinary Bladder Neoplasms · United States | 2 | Completed | Halozyme Therapeutics | Aug 11, 2009 | 27 |
| NCT00311519Healthy · United States | 4 | Completed | Halozyme Therapeutics | 50 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “rHuPH20”, 5 entries
- “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
- “recombinant human hyaluronidase”, 3 entries
Codes read as this program: RHUPH20.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 6 studies
- Myasthenia Gravis, 5 studies
- Primary Immunodeficiency Diseases, 4 studies
- Dehydration, 4 studies
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.